# Table of Contents

## Part-A

1. **Introduction**  
   1-2

2. **Review of literature**  
   3-23
   - 2.1. Diabetes 3
   - 2.2. Complications 4
   - 2.3. Regulation of glucose homeostasis 5
   - 2.4. Pathogenesis 5
   - 2.5. Current oral hypoglycemic agents 6
   - 2.6. Incretin and incretin effect 10
   - 2.7. GLP-1 signaling 13
   - 2.8. Dipeptidyl peptidase IV (DPP-IV) and DPP-IV inhibitors 16
   - 2.9. Pharmacology of DPP-IV inhibitors 17
   - 2.10. Development of DPP-IV inhibitors 18
   - 2.11. Mechanism of DPP-IV inhibitor action 19
   - 2.12. DPP-IV inhibitors selectivity 20
   - 2.13. Effect of DPP-IV inhibitors on glucagon secretion 21
   - 2.15. Drug profile 22
     - 2.15.1. Vildagliptin 22
     - 2.15.2. PKF-275-055 23

3. **Need of the present investigation**  
   24-26

4. **Aims**  
   27

5. **Materials and methods**  
   28-35
   - 5.1. Materials 28
   - 5.2. Animals 28
   - 5.3. Eight weeks chronic daily dosing 28
   - 5.4. Oral glucose tolerance test (OGTT) in diabetic rats 29
   - 5.5. Plasma insulin, GLP-1, and DPP-IV levels during the OGTT in diabetic rats 29
5.6. Oral glucose tolerance test (OGTT) in normal rats
5.7. Glycated hemoglobin (HbA1c) assay
5.8. Homeostatic model assessment for insulin resistance
5.9. Pancreatic nitrate/nitrite assay
5.10. Estimation of tumor necrosis factor-α
5.11. Estimation of total proteins
5.12. Glycogen contents in liver and muscles
5.13. Gastrointestinal functions in diabetic rats
5.14. RNA isolation and Real-time PCR analysis
5.15. GLUT-2 expressions in liver and GLUT-4 expressions in soleus muscle
5.16. Immunocytochemistry
5.17. DNA Fragmentation Assay
5.18. Statistical analysis

6. Results
6.1. Effect of DPP-IV inhibitors on body weight and blood glucose
6.2. Effects of DPP-IV inhibitors on blood glucose levels during the OGTT in diabetic rats
6.3. Effects of DPP-IV inhibitors on blood glucose levels during the OGTT in normal rats
6.4. Effects of DPP-IV inhibitors on plasma insulin, GLP-1, and DPP-IV levels during the OGTT in diabetic rats
6.5. Effect of chronic daily dosing of DPP-IV inhibitors on glycated hemoglobin (HbA1c), HOMA-Index, and β-cell function in diabetic rats
6.6. Effect of DPP-IV inhibitors on total proteins in serum and pancreatic homogenates
6.7. Effect of DPP-IV inhibitors on rat TNF-alpha concentrations
6.8. Effect of DPP-IV inhibitors nitric oxide concentrations in serum and pancreatic homogenates
6.9. Effect of DPP-IV inhibitors on liver and muscle glycogen
6.10. Effects of DPP-IV inhibitors on gastrointestinal functions in diabetic rats

6.11. Effects of vildagliptin and PKF-275-055 on muscle GLUT-4 mRNA, liver SREBP1c mRNA, and pancreatic GLP-1 mRNA concentrations of diabetic rats

6.12. Effect of vildagliptin and PKF-275-055 on liver GLUT-2 and muscle GLUT-4 expression

6.13. Effect of chronic daily dosing of vildagliptin and PKF-275-055 on histopathologic changes and cell apoptosis in the pancreata of diabetic rats

7. Discussion

8. Conclusion

Part-B

1. Introduction

2. Review of literature
   2.1. Diabetes mellitus
   2.2. Pancreatic islets
   2.3. Microcirculation of the islets
   2.4. Dipeptidyl-peptidase IV (DPP-4) and DPP-4 inhibitors
   2.5. Pharmacology of DPP-4 inhibitors
   2.6. Mechanisms of DPP-4 inhibitor action

3. Need of the present investigation

4. Aims

5. Materials and Methods
   5.1. Materials
   5.2. Animals
   5.3. Islet blood flow measurement in normal and diabetic rats
   5.4. Measurement of hemodynamic parameters in normal rats
   5.5. Isolation and culture of islets from normal rats
   5.6. Measurement of cytosolic Ca²⁺ concentrations
5.7. Statistical analysis

6. Results

6.1. Effect of DPP-IV inhibitors on blood glucose concentrations

6.2. Effect of DPP-IV inhibitors on plasma insulin concentrations

6.3. Effect of DPP-IV inhibitors on plasma GLP-1 concentrations

6.4. Effect of DPP-IV inhibitors on serum nitric oxide concentrations

6.5. Effect of DPP-IV inhibitors on total pancreatic blood flow, islet blood flow, IBF (% PBF) and cardiac output

6.6. Effect of DPP-IV inhibitors on hemodynamic parameters

6.7. Effect of DPP-IV inhibitors on cytosolic Ca\(^{2+}\) concentrations

7. Discussion

8. Conclusion

9. References

10. Publications onwards